Quick answer : Ketamine can produce significant improvement in some people with treatment-resistant depression, but it does not work for everyone. Depression is biologically complex, and treatment response may be influenced by sleep, inflammation, metabolic health, medications, hormones, substance use, trauma, and the underlying diagnosis. When someone does not respond as expected, it may be more useful to reassess the entire clinical picture rather than simply continuing the same treatment.
One of the biggest misconceptions about ketamine therapy is that it should work for everyone with depression. Ketamine can produce rapid and sometimes significant improvement, particularly in people who have not responded adequately to conventional antidepressants. However, people can respond very differently to treatment.
Depression does not have one single biological cause. Two people can have similar depression symptoms while experiencing very different factors that contribute to those symptoms.
For example, one person may have severe sleep disruption or undiagnosed sleep apnea. Another may have metabolic health concerns, chronic inflammation, hormonal abnormalities, unresolved trauma, substance use, or a different underlying psychiatric condition.
Ketamine also works differently from conventional antidepressants. Rather than primarily targeting serotonin or norepinephrine, ketamine affects glutamate signaling and pathways involved in synaptic plasticity.
These effects may help the brain form and strengthen new neural connections. However, increased neuroplasticity does not necessarily address every factor contributing to someone’s depression.
Researchers continue to study why some people respond to ketamine while others do not. Studies have examined clinical characteristics, medications, biomarkers, sleep patterns, inflammatory markers, and other potential predictors.
Some factors appear promising. However, no single blood test, brain scan, questionnaire, or clinical characteristic can currently predict with certainty whether an individual patient will respond to ketamine.
This is one reason we pay attention to the pattern of improvement during an initial treatment series. Mood is important, but it is not the only measure of progress.
We also look for changes in:
Motivation
Rumination
Anxiety
Sleep
Energy
Social engagement
Ability to experience pleasure
Daily functioning
Functional improvements may sometimes appear before a patient notices a dramatic change in overall mood. Tracking these changes can provide a more complete picture of how someone is responding to treatment.
When someone experiences little or no improvement, the answer should not automatically be to give more ketamine. Instead, it may be time to reconsider the diagnosis, treatment protocol, medications, and other factors that could be contributing to persistent symptoms.
Sleep deserves particular attention. Poor sleep, significant insomnia, and untreated obstructive sleep apnea can contribute to fatigue, cognitive difficulties, emotional regulation problems, and depressive symptoms.
A patient may continue to experience these symptoms even while receiving appropriate psychiatric treatment. Identifying and addressing an underlying sleep problem can therefore become an important part of the overall treatment plan.
Metabolic health may also play a role in depression. Insulin resistance, obesity, physical inactivity, and other metabolic abnormalities are associated with depression and may influence overall health.
For selected patients, additional medical factors may deserve evaluation. These can include thyroid function, nutritional deficiencies, hormonal factors, inflammation, alcohol or cannabis use, and other health concerns.
The goal is not to assume that one of these factors explains a patient’s depression. Instead, a broader evaluation can help identify issues that may be contributing to persistent symptoms.
Medications are another important consideration. A complete medication review may identify drugs that contribute to fatigue, cognitive symptoms, or sleep disruption.
The review can also help the clinician consider whether other medications or treatment combinations could influence the patient’s overall response to ketamine.
Sometimes the most important step is reconsidering what is actually being treated. Bipolar depression, trauma-related disorders, substance-related symptoms, sleep disorders, ADHD, medical conditions, and other problems can overlap with major depressive disorder.
This does not mean that everyone with treatment-resistant depression has been misdiagnosed. It does mean that when several appropriate treatments have failed, periodically revisiting the diagnosis can be reasonable.
A patient who has repeatedly been treated for unipolar depression may have a history that warrants additional evaluation. Periods of unusually high energy, reduced need for sleep, impulsivity, or antidepressant-associated mood elevation can raise questions about a possible bipolar spectrum disorder.
Identifying that distinction can significantly change the treatment strategy. A careful diagnostic evaluation helps ensure that treatment targets the condition actually driving the symptoms.
Another way to think about ketamine is that it may create a period of increased neural flexibility rather than simply functioning as a conventional antidepressant.
If the brain becomes more capable of changing, what happens during that period may matter. Psychotherapy, exercise, restorative sleep, nutrition, meaningful social connection, stress regulation, and changes in persistent behavioral patterns may all support healthier patterns over time.
This is one reason our approach at Seaside Ketamine extends beyond the infusion itself. We consider ketamine one part of a broader treatment process rather than the entire solution.
Our goal is to address both immediate symptoms and the environment in which the brain is trying to recover. For some patients, ketamine may become an important part of that process while other interventions provide additional support.
Not responding to ketamine does not mean that someone has “untreatable depression.” Instead, it may indicate that the treatment plan deserves another look.
There may be other evidence-based treatment options to consider. Contributing factors may also remain unidentified or inadequately addressed.
At that point, the more useful question may not be, “What medication should we try next?”
Instead, it may be:
“What could we be missing?”
That question is central to how we approach treatment-resistant depression at Seaside Ketamine. When treatment does not produce the expected response, we look beyond the medication itself and consider the broader clinical picture.
Many IV ketamine protocols use an initial series of treatments rather than judging response after a single infusion. The appropriate number varies according to the diagnosis, response trajectory, tolerability, and treatment protocol. Your treating clinician should evaluate whether there are meaningful changes occurring during the series and whether continuing treatment makes clinical sense.
Yes. The timing of response varies. Some people notice improvement after the first few treatments, while others improve later during the initial series. A lack of dramatic improvement after one infusion does not necessarily mean someone will not respond, although continued absence of improvement should prompt reassessment.
The next step should usually involve reassessing the broader clinical picture rather than automatically continuing the same treatment indefinitely. Diagnosis, medications, sleep, metabolic health, substance use, medical conditions, trauma, and other potential contributors may need to be considered alongside alternative treatment options.
